glp-1 cardiovascular outcomes trial august 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Pendulum Pack Size:4-Pack Adding a GLP-1 receptor

glp-1 cardiovascular outcomes trial august 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Pendulum Pack Size:4-Pack Adding a GLP-1 receptor

Adding a GLP-1 receptor agonist was not associated with a lower likelihood of discontinuing existing basal insulin therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation

First, our findings may have limited generalizability since they were derived from patients who predominately identify as white and are receiving care at a single large regional healthcare system

Pendulum

Pack Size:4-Pack

Nat Commun 2013